A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 Diabetes
Recruiting
Phase 3
Interventional Study
Diabetes Type 1
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 36 (estimated)
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if Empagliflozin and Semaglutide, individually and combined, added to Automated Insulin Delivery (AID) works to improve time-in-range in adults living with Type 1 Diabetes. It will also evaluate the safety of Empagliflozin and Semaglutide in this context.
The primary hypothesis of this study is :
\- The combination therapy of semaglutide and empagliflo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
The inclusion criteria at the time of enrollment are:
* Males and females aged 18 or older.
* Clinical diagnosis of T1D for at least one year.
* Use of AID system for at least three months.
* Body Mass Index (BMI) ≥ 23 kg/m2.
The exclusion criteria are:
* Use of GLP1-RA within one month of admiss…
Contacts